Trial-Results center  
Clinical trial results database in cardiology Feedback    Home


Related trials

SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent

BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent

BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent

SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent

RESOLUTE All comers, 2010 - zotarolimus eluting stent vs everolimus eluting stent

GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent

ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent

ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

BARI 2D, 2009 - CABG or PCI vs medical treatment

PASEO, 2009 - drug-eluting stents vs bare-metal stent

SYNTAX, 2009 - paclitaxel eluting stent vs CABG

ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

Thiele, 2009 - sirolimus ES vs MIDCAB

ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent

ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent

ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent



See also:

  • All coronary artery disease clinical trials
  • All clinical trials of myocardial revascularization
  • All clinical trials of zotarolimus eluting stent
    		•  

    ZEST (vs PES) study, 2009

    [NCT00418067] download pdf: zotarolimus eluting stent | myocardial revascularization for coronary artery disease

    Treatments

    Studied treatment zotarolimus-eluting stents
    Control treatment paclitaxel-eluting stents
    Concomittant treatment aspirin and clopidogrel prior to the procedure. Aspirin was administered indefinitly and clopidogrel for at least 12 months. Heparin during PCI. Glycoprotein IIb/IIIa inhibitors at discretion

    Patients

    Patients Patients with coronary artery disease
    Exclusion criteria severe left ventricular dysfunction (left ventricular ejection fraction <25%); cardiogenic shock; renal insufficiency; liver dysfunction; left main stenosis; in-stent restenosis of a drug-eluting stent; poor life expectancy
    Baseline characteristics
    age 62y 
    diabetes (%) 30% 
    unstable angina (%) 55% 
    Female (%) 34% 
    bifurcated lesions 15% 
    ostial lesion 7% 
    multi vessels patients 47% 
    No of stent per lesions 1.2 
    No of lesions per patients 1.4 

    Method and design

    Randomized effectives 883 / 884 (studied vs. control)
    Blinding NA
    Follow-up duration 1 year
    Primary endpoint death, myocardial infarction, TLR
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    MACE

    89 / 883
         126 / 884
         0,71 [0,55;0,91]

    All cause death

    6 / 883
         10 / 884
         0,60 [0,22;1,65]

    MI (fatal and non fatal)

    47 / 883
         62 / 884
         0,76 [0,53;1,10]

    target lesion revascularisation

    43 / 883
         66 / 884
         0,65 [0,45;0,95]

    Stent thrombosis (any, end of follow up)

    4 / 883
         6 / 884
         classic 0,67 [0,19;2,36]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    MACE 89 / 883 (10,1%) 126 / 884 (14,3%) 0,71 [0,55;0,91]
    All cause death 6 / 883 (0,7%) 10 / 884 (1,1%) 0,60 [0,22;1,65]
    MI (fatal and non fatal) 47 / 883 (5,3%) 62 / 884 (7,0%) 0,76 [0,53;1,10]
    target lesion revascularisation 43 / 883 (4,9%) 66 / 884 (7,5%) 0,65 [0,45;0,95]
    Stent thrombosis (any, end of follow up) 4 / 883 (0,5%) 6 / 884 (0,7%) 0,67 [0,19;2,36]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    MACE 10,08% 14,25% -41,7‰
    All cause death 6,80‰ 1,13% -4,5‰
    MI (fatal and non fatal) 5,32% 7,01% -16,9‰
    target lesion revascularisation 4,87% 7,47% -26,0‰
    Stent thrombosis (any, end of follow up) 4,53‰ 6,79‰ -2,3‰

    Meta-analysis of all similar trials:

    Drug eluting stent in coronary artery disease for all type of patients

    Drug eluting stent in coronary artery disease for unparticular patients

    myocardial revascularization in coronary artery disease for all type of patient



    Reference(s)

    Trials register # NCT00418067
    • Seung-Jung Park . Comparison of Sirolimus and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial. ACC.09/i2, Orlando, FL, March 2009
      Pubmed | Hubmed | Fulltext
    • Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJ. Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial.. J Am Coll Cardiol 2010 Oct 5;56:1187-95 - 10.1016/j.jacc.2010.03.086
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend